The potential clinical value of the reversible role in the insulin/leptin receptor phosphorylation and signaling provides a major stimulus to the realization that inhibiting PTP1B can alleviate insulin resistance, normalize glycaemic control and address both Type 2 diabetes and obesity [7]–[10]. Here, PTPN1 is linked to obesity due to melanocortin 4 receptor deficiency.